One of the reasons I like biotech is because the average punter doesn't appreciate the evidence-based aspect to their technology.
The fact that Uscom 1A has recently been included in international clinical guidelines to me is huge achievement and a validation that the current SP has not factored in. It should translate into future sales and attract attention from other large co's in the area.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.759M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 46000 | 1 |
View Market Depth
| Last trade - 16.21pm 27/06/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable